Literature DB >> 28785198

Fracture Risk in Prostate Cancer during Hormonal Therapy.

Takashi Kawahara1,2, Shusei Fusayasu1, Shinji Ohtake1, Hiroki Ito1, Yasuhide Miyoshi2, Masahiro Yao1, Hiroji Uemura2.   

Abstract

Entities:  

Year:  2017        PMID： 28785198      PMCID： PMC5527182          DOI： 10.1159/000447162

Source DB:  PubMed          Journal:  Curr Urol        ISSN： 1661-7649


× No keyword cloud information.
  5 in total

Review 1.  Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.

Authors:  C Schulman; J Irani; M Aapro
Journal:  BJU Int       Date:  2012-06       Impact factor: 5.588

2.  Fracture risk in men with prostate cancer: a population-based study.

Authors:  L Joseph Melton; Michael M Lieber; Elizabeth J Atkinson; Sara J Achenbach; Horst Zincke; Terry M Therneau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

3.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

Review 4.  The impact of osteoporosis in men treated for prostate cancer.

Authors:  Michael G Oefelein; Martin I Resnick
Journal:  Urol Clin North Am       Date:  2004-05       Impact factor: 2.241

5.  Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.

Authors:  Vivek K Wadhwa; Robin Weston; Rahul Mistry; Nigel J Parr
Journal:  BJU Int       Date:  2009-03-11       Impact factor: 5.588
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.